NYSE:WST - West Pharmaceutical Services Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $310.00
  • Forecasted Upside: 15.80 %
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$267.71
▼ -8.01 (-2.91%)
1 month | 3 months | 12 months
Get New West Pharmaceutical Services Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for WST and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for WST

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$310.00
▲ +15.80% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for West Pharmaceutical Services in the last 3 months. The average price target is $310.00, with a high forecast of $350.00 and a low forecast of $280.00. The average price target represents a 15.80% upside from the last price of $267.71.
Buy
The current consensus among 3 investment analysts is to buy stock in West Pharmaceutical Services. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/3/2019
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/1/2019
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
11/30/2019
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
2/28/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/28/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/26/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/25/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
11/24/2020

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/9/2020KeyCorpInitiated CoverageOverweight$350.00High
i
10/13/2020StephensInitiated CoverageEqual Weight$300.00High
i
7/21/2020Bank of AmericaUpgradeNeutral ➝ Buy$280.00Low
i
4/24/2020Bank of AmericaUpgradeUnderperform ➝ Neutral$145.00 ➝ $200.00High
i
Rating by Derik De Bruin at Bank of America Co.
12/12/2019Bank of AmericaDowngradeNeutral ➝ Underperform$135.00Medium
i
7/26/2019Bank of AmericaUpgradeUnderperform ➝ NeutralHigh
i
5/1/2019Jefferies Financial GroupDowngradeBuy ➝ Hold$122.00Medium
i
4/23/2019William BlairInitiated CoverageOutperform ➝ Outperform$112.16Medium
i
Rating by J. Kreger at William Blair
4/25/2018Bank of AmericaDowngradeNeutral ➝ Underperform$85.00High
i
1/24/2018The Goldman Sachs GroupInitiated CoverageNeutral ➝ Neutral$110.00Low
i
10/27/2017Wells Fargo & CompanyBoost Price TargetOutperform$105.00 ➝ $112.00N/A
i
10/17/2017Bank of AmericaDowngradeBuy ➝ Neutral$98.00N/A
i
10/3/2017StephensInitiated CoverageEqual ➝ Equal Weight$99.00Medium
i
9/15/2017Jefferies Financial GroupUpgradeHold ➝ Buy$96.00 ➝ $115.00High
i
6/8/2017Jefferies Financial GroupReiterated RatingHold$90.00Low
i
4/28/2017Jefferies Financial GroupReiterated RatingHold$82.00 ➝ $90.00Low
i
2/21/2017Jefferies Financial GroupReiterated RatingHold$82.00N/A
i
1/24/2017Jefferies Financial GroupBoost Price TargetHold$76.00 ➝ $82.00N/A
i
12/23/2016Janney Montgomery ScottReiterated RatingBuyN/A
i
10/28/2016Wells Fargo & CompanyUpgradeMarket Perform ➝ OutperformN/A
i
9/26/2016Janney Montgomery ScottReiterated RatingBuy ➝ Fair Value$90.00 ➝ $72.55N/A
i
9/21/2016Wells Fargo & CompanyDowngradeOutperform ➝ Market PerformN/A
i
8/4/2016Jefferies Financial GroupReiterated RatingHoldN/A
i
7/29/2016Jefferies Financial GroupBoost Price TargetHold$67.00 ➝ $77.00N/A
i
6/9/2016Jefferies Financial GroupReiterated RatingHold$67.00N/A
i
5/13/2016Janney Montgomery ScottReiterated RatingBuy$69.00 ➝ $90.00N/A
i
Rating by Paul Knight at Janney Montgomery Scott
3/22/2016Wells Fargo & CompanyInitiated CoverageOutperformN/A
i
1/7/2016Janney Montgomery ScottInitiated CoverageBuy$69.00N/A
i
(Data available from 11/25/2015 forward)
West Pharmaceutical Services logo
West Pharmaceutical Services, Inc. manufactures and sells containment and delivery systems for injectable drugs and healthcare products in the United States, Germany, Ireland, France, Other European countries, and internationally. The company operates through two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, and washing and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of components and devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. This segment serves pharmaceutical, diagnostic, and medical device companies. It distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors. The company was founded in 1923 and is headquartered in Exton, Pennsylvania.
Read More

Today's Range

Now: $267.71
$267.21
$275.50

50 Day Range

MA: $286.79
$271.40
$301.66

52 Week Range

Now: $267.71
$124.53
$305.00

Volume

461,127 shs

Average Volume

589,044 shs

Market Capitalization

$19.79 billion

P/E Ratio

70.64

Dividend Yield

0.25%

Beta

1.13